They provide a strong rationale for the development and implementation of dual inhibition strategies aimed at concurrently targeting both the EGFR and RET signaling pathways, with the potential to overcome resistance, enhance therapeutic efficacy, and improve patient outcomes in this molecularly defined subset of NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.